Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Clinicopathologic and Diagnostic Significance of p53 Protein Expression in Papillary Thyroid Carcinoma

  • Shin, Mi Kyung (Department of Pathology, Kangnam Sacred Heart Hospital, Hallym University Medical Center) ;
  • Kim, Jeong Won (Department of Pathology, Kangnam Sacred Heart Hospital, Hallym University Medical Center)
  • Published : 2014.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: p53 protein expression has been detected immunohistochemically in papillary thyroid carcinoma(PTC). We investigated the relations between its expression and clinicopathologic features and its significance as a diagnostic marker. Materials and Methods: We compared and evaluated 93 patients in whom thyroidectomy with lymph node dissection had been performed to treat PTC for clinicopathologic significance and 102 patients with 23 papillary thyroid overt carcinomas (POC), 57 papillary thyroid microcarcinomas(PMC), 5 follicular adenomas (FA), 5 Hashimoto's thyroiditis (HT) and 12 nodular hyperplasias (NH) for significance as a diagnostic marker. Expression of p53 protein was evaluated immunohistochemically in sections of paraffinembedded tissue. Results: Statistical analysis showed significantly different expression of p53 in PTC versus other benign thyroid lesions (BTL).The diagnostic sensitivity and specificity were 85.0% and 72.7%, respectively. Overexpression of p53 protein was observed in 44 of the 93 PTC cases (47.3%), but no significant correlation between p53 protein overexpression and clinicopathologic features (age, size, multiplicity, lymph node metastasis, extrathyroidal extension and vascular invasion) was noted. Conclusions: p53 is valuable to distinguish PTC from other BTL, but there is no correlation between p53 protein overexpression and clinicopathologic features.

Keywords

References

  1. Balta AZ, Filiz AI, Kurt Y, et al (2012). Prognostic value of oncoprotein expressions in thyroid papillary carcinoma. Med Oncol, 29, 734-41. https://doi.org/10.1007/s12032-011-9969-x
  2. Cvejic D, Selemetjev S, Savin S, et al (2008). Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid. Pathology, 40, 475-80. https://doi.org/10.1080/00313020802026989
  3. Dellis RA, Lloyd RV, Heitz U, Eng C (2004). Pathology and Genetics. Tumours of Endocrine organs. Lyon: World Health Organization, IARC Press.
  4. El Demellawy D, Nasr A, Alowami S (2008). Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol, 6, 3-5.
  5. Gauchotte G, Philippe C, Lacomme S, et al (2011). BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis. Pathology, 43, 447-52. https://doi.org/10.1097/PAT.0b013e3283486178
  6. Hamzany Y, Soudry E, Strenov Y, et al (2012). Early death from papillary thyroid carcinoma. Am J Otolaryngol, 33, 104-8. https://doi.org/10.1016/j.amjoto.2011.04.002
  7. Hansen JE, Fischer LK, Chan G, et al (2008). Antibody-mediated p53 protein therapy prevents liver metastasis in vivo. Cancer Res, 67, 1769-74.
  8. Horie S, Maeta H, Endo K, et al (2001). Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features. Pathol Int, 51, 11-5. https://doi.org/10.1046/j.1440-1827.2001.01159.x
  9. Hosal SA, Apel RL, Freeman JL, et al (1997). Immunohistochemical localization of p53 in human thyroid neoplasms: correlation with biological behavior. Endocr Pathol, 18, 21-8.
  10. Jung TS, Kim K-S, Oh YL, Jung JH (2007). p53, p21 and Bcl-2 protein expression and the clinical significance in papillary thyroid carcinoma. J Korean Endo Soc, 22, 98-104. https://doi.org/10.3803/jkes.2007.22.2.98
  11. Karlidag T, Cobanoglu B, Keles E, et al (2007). Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. Am J Otolaryngol, 28, 31-6. https://doi.org/10.1016/j.amjoto.2006.06.008
  12. Liu MC and Gelmann EP (2002). P53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol, 29, 246-57. https://doi.org/10.1053/sonc.2002.32900
  13. Kim BS, Kang KH, Lim YA, Kim LS (2009). Clinical significance of p53, Ki-67 and Galectin-3 expressions in papillary thyroid carcinoma. J Korean Surg Soc, 77, 29-36. https://doi.org/10.4174/jkss.2009.77.1.29
  14. Morita N, Ikeda Y, Takami H (2008). Clinical significance of p53 protein expression in papillary thyroid carcinoma. World J Surg, 32, 2617-22. https://doi.org/10.1007/s00268-008-9756-9
  15. Nasir A, Catalano E, Calafati S, et al (2004). Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid. in vivo, 18, 189-95.
  16. Omar E, Madhavan M, Othman NH (2004). Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications. Pathology, 36, 152-9. https://doi.org/10.1080/00313020410001671993
  17. Parameswaran R, Brooks S, Sadler GP (2010). Molecular pathogenesis of follicular cell derived thyroid cancers. Int J Surg, 8, 186-93. https://doi.org/10.1016/j.ijsu.2010.01.005
  18. Park KY, Koh JM, Kim YI, et al (1998). Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin Endocrinol (Oxf), 49, 317-23. https://doi.org/10.1046/j.1365-2265.1998.00515.x
  19. Park YK, Park HR, Chi SG, Ushigome S, Unni KK (2001). Overexpression of p53 and absent genetic mutation in clear cell chondrosarcoma. Int J Oncol, 19, 353-7.
  20. Park MI, Kang DY (2006). Usefulness of Galectin-3, cytokeratin 19, p53 and Ki-67 for the differential diagnosis of thyroid tumors. Korean J Pathol, 40, 86-92.
  21. Tan A, Etit D, Bayol U, Altinel D, Tan S (2011). Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol, 15, 108-16. https://doi.org/10.1016/j.anndiagpath.2010.11.005
  22. Zafon C, Obiols G, Castellvi J, et al (2007). Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma. Histopathology, 50, 225-31. https://doi.org/10.1111/j.1365-2559.2006.02555.x

Cited by

  1. No Evidence of Association of the Arg72Pro p53 Gene Polymorphism with Cancer Risk in the Saudi Population: a Meta-Analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5663
  2. The TP53 intron 6 G13964C Polymorphism and Risk of Thyroid and Breast Cancer Development in the Iranian Azeri Population vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.3073
  3. p53, Cyclin D1, p21 (WAF1) and Ki-67 (MIB1) Expression at Invasive Tumour Fronts of Oral Squamous Cell Carcinomas and Development of Local Recurrence vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1243
  4. Decreased expression of p27 is associated with malignant transformation and extrathyroidal extension in papillary thyroid carcinoma vol.37, pp.3, 2016, https://doi.org/10.1007/s13277-015-4163-y
  5. Correlation of BRAF mutation and SUVmax levels in thyroid cancer patients incidentally detected in 18F-fluorodeoxyglucose positron emission tomography vol.55, pp.1, 2017, https://doi.org/10.1007/s12020-016-1128-x